Yanan Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yanan Kong has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoming Xie
Sun Yat-sen University Cancer Center 1 Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, China
23 shared publications Xinhua Xie
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
16 shared publicationsHailin Tang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
12 shared publicationsLu Yang
Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China
11 shared publicationsJiaoli Guo
Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong, China
10 shared publicationsNing Lv
Department of Medical Imaging and Image-guided Therapy, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
10 shared publications
Latest Publications
- 9 June 2026
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 45 (2) , 39
Antibody-drug conjugates in breast cancer brain and leptomeningeal metastases: mechanistic insights and therapeutic progress
Antibody-drug conjugates (ADCs) are targeted therapies that employ monoclonal antibodies to deliver potent cytotoxic agents to cancer cells. The treatment of breast cancer with brain and leptomeningeal metastases has long been limited by the assumption that the blood-brain barrier (BBB) and blood–cerebrospinal fluid barrier (BCSFB) restrict the penetration of large molecules into the central nervous system (CNS). However, recent evidence from several trails (DESTINY-Breast12, DEBBRAH, TUXEDO-3, etc.) challenges this paradigm. In these studies, trastuzumab deruxtecan, a HER2-targeted ADC, demonstrated notable intracranial responses in patients with active CNS disease, suggesting that CNS barriers are dynamically remodeled within the tumor microenvironment to permit drug access. These findings have renewed interest in understanding how macromolecular ADCs penetrate the CNS and exert anti-tumor effects. By integrating emerging clinical evidence with key pharmacological determinants and tumor-associated microenvironmental changes, this review delineates the mechanisms governing ADC activity in brain metastases and identifies critical factors underlying intracranial response. Collectively, these insights provide a mechanistic framework to guide the rational design of next-generation ADCs and optimize therapeutic strategies for patients with advanced CNS involvement.
- 9 June 2026
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 45 (2) , 39
Antibody-drug conjugates in breast cancer brain and leptomeningeal metastases: mechanistic insights and therapeutic progress
Antibody-drug conjugates (ADCs) are targeted therapies that employ monoclonal antibodies to deliver potent cytotoxic agents to cancer cells. The treatment of breast cancer with brain and leptomeningeal metastases has long been limited by the assumption that the blood-brain barrier (BBB) and blood–cerebrospinal fluid barrier (BCSFB) restrict the penetration of large molecules into the central nervous system (CNS). However, recent evidence from several trails (DESTINY-Breast12, DEBBRAH, TUXEDO-3, etc.) challenges this paradigm. In these studies, trastuzumab deruxtecan, a HER2-targeted ADC, demonstrated notable intracranial responses in patients with active CNS disease, suggesting that CNS barriers are dynamically remodeled within the tumor microenvironment to permit drug access. These findings have renewed interest in understanding how macromolecular ADCs penetrate the CNS and exert anti-tumor effects. By integrating emerging clinical evidence with key pharmacological determinants and tumor-associated microenvironmental changes, this review delineates the mechanisms governing ADC activity in brain metastases and identifies critical factors underlying intracranial response. Collectively, these insights provide a mechanistic framework to guide the rational design of next-generation ADCs and optimize therapeutic strategies for patients with advanced CNS involvement.
- Top Cited PapersOpen Access
- 21 January 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
piR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer
Therapeutic target for triple-negative breast cancer (TNBC) brain metastases remains a critical unmet clinical challenge. The roles of PIWI-interacting RNA
- 21 January 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Top Cited PapersOpen AccesspiR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer
Therapeutic target for triple-negative breast cancer (TNBC) brain metastases remains a critical unmet clinical challenge. The roles of PIWI-interacting RNA
- Open Access
- 12 December 2025
- Published by Elsevier in The Breast
- Vol. 85, 104678
A prognostic gene model with psychological stress-related genes captures immune activation in breast cancer
- 12 December 2025
- Published by Elsevier in The Breast
- Vol. 85, 104678
Open AccessA prognostic gene model with psychological stress-related genes captures immune activation in breast cancer
- 27 April 2024
- Published by Elsevier in Cancer Letters
- Vol. 592, 216907
circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer
- 27 April 2024
- Published by Elsevier in Cancer Letters
- Vol. 592, 216907
circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 through 4 from Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells
PDF - 398K, Figure S1. Tissue distribution of CMV-Luc and AT-VISA-Luc in male BABL/c nu/nu mice not bearing tumors; Figure S2. In vitro killing effect of BikDD; Figure S3. AT-VISA-BikDD inhibits tumor growth more effectively than CMV-BikDD in LnCAP orthotopic model; Figure S4. The expression of BikDD of prostate tissues in normal male nude mice treated with CMV-BikDD, AT-VISA-BikDD, and controls.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 through 4 from Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells
PDF - 398K, Figure S1. Tissue distribution of CMV-Luc and AT-VISA-Luc in male BABL/c nu/nu mice not bearing tumors; Figure S2. In vitro killing effect of BikDD; Figure S3. AT-VISA-BikDD inhibits tumor growth more effectively than CMV-BikDD in LnCAP orthotopic model; Figure S4. The expression of BikDD of prostate tissues in normal male nude mice treated with CMV-BikDD, AT-VISA-BikDD, and controls.
- Top Cited PapersOpen Access
- 13 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, we identify FGFR4 as an essential gene following anti-HER2 treatment. FGFR4 inhibition enhances susceptibility to anti-HER2 therapy in resistant breast cancer. Mechanistically, m6A-hypomethylation regulated FGFR4 phosphorylates GSK-3β and activates β-catenin/TCF4 signaling to drive anti-HER2 resistance. Notably, suppression of FGFR4 dramatically diminishes glutathione synthesis and Fe2+ efflux efficiency via the β-catenin/TCF4-SLC7A11/FPN1 axis, resulting in excessive ROS production and labile iron pool accumulation. Ferroptosis, a unique iron-dependent form of oxidative cell death, is triggered after FGFR4 inhibition. Experiments involving patient-derived xenografts and organoids reveals a synergistic effect of anti-FGFR4 with anti-HER2 therapy in breast cancer with either intrinsic or acquired resistance. Together, these results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer.
- 13 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Top Cited PapersOpen AccessN6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, we identify FGFR4 as an essential gene following anti-HER2 treatment. FGFR4 inhibition enhances susceptibility to anti-HER2 therapy in resistant breast cancer. Mechanistically, m6A-hypomethylation regulated FGFR4 phosphorylates GSK-3β and activates β-catenin/TCF4 signaling to drive anti-HER2 resistance. Notably, suppression of FGFR4 dramatically diminishes glutathione synthesis and Fe2+ efflux efficiency via the β-catenin/TCF4-SLC7A11/FPN1 axis, resulting in excessive ROS production and labile iron pool accumulation. Ferroptosis, a unique iron-dependent form of oxidative cell death, is triggered after FGFR4 inhibition. Experiments involving patient-derived xenografts and organoids reveals a synergistic effect of anti-FGFR4 with anti-HER2 therapy in breast cancer with either intrinsic or acquired resistance. Together, these results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer.
- Open Access
- 1 August 2021
- Published by AME Publishing Company in Gland Surgery
- Vol. 10 (8) , 2428-2437
Does Mammotome biopsy affect surgery option and margin status of breast conserving surgery in breast cancer?
Background: The Mammotome, an image-guided, usually ultrasound-guided vacuum-assisted breast biopsy (US-VABB) system, has been widely used in the early diagnosis of breast disease and the complete excision of benign lesions. However, in some malignant lesions underestimated by U.S., whether Mammotome biopsy would affect the surgery option, especially the margin status in breast-conserving surgery (BCS), has never been studied. Methods: Between 2015 and 2019, 198 patients with 200 lesions who have been diagnosed with breast cancer by Mammotome elsewhere received surgery by pathological confirmation in our center. The clinicopathological characteristics, surgery options, therapies, and the details of the specimen, such as margin status of BCS, tumor residual after VABB, and hematoma were reviewed. Results: Among 200 lesions, 90% were evaluated below US-BIRADS 4b before Mammotome biopsy and 94.5% with a tumor size ≤3 cm. 131 patients received mastectomy (66.2%) and 67 received BCS (33.8%). Hematoma and tumor residual were observed in 37.5% and 71.5% of all lesions, respectively. There is a higher incidence of hematoma in the mastectomy group than in the BCS group (44.4% vs. 23.9%, P=0.005). In BCS group, the positive margin was found in 7 patients at first examination including four focals with re-excision, two extensive with mastectomy and one focal but refusing further surgery. The ultimate success rate of BCS was 95.5%. Margin positivity correlated with tumor residual (P=0.044) but not with hematoma. Conclusions: Mammotome biopsy might lead to hematoma and tumor residual; however, it is not the determinant factor for a surgery option, and BCS is feasible through a complete excision of tumor residual to acquire negative margin.
- 1 August 2021
- Published by AME Publishing Company in Gland Surgery
- Vol. 10 (8) , 2428-2437
Open AccessDoes Mammotome biopsy affect surgery option and margin status of breast conserving surgery in breast cancer?
Background: The Mammotome, an image-guided, usually ultrasound-guided vacuum-assisted breast biopsy (US-VABB) system, has been widely used in the early diagnosis of breast disease and the complete excision of benign lesions. However, in some malignant lesions underestimated by U.S., whether Mammotome biopsy would affect the surgery option, especially the margin status in breast-conserving surgery (BCS), has never been studied. Methods: Between 2015 and 2019, 198 patients with 200 lesions who have been diagnosed with breast cancer by Mammotome elsewhere received surgery by pathological confirmation in our center. The clinicopathological characteristics, surgery options, therapies, and the details of the specimen, such as margin status of BCS, tumor residual after VABB, and hematoma were reviewed. Results: Among 200 lesions, 90% were evaluated below US-BIRADS 4b before Mammotome biopsy and 94.5% with a tumor size ≤3 cm. 131 patients received mastectomy (66.2%) and 67 received BCS (33.8%). Hematoma and tumor residual were observed in 37.5% and 71.5% of all lesions, respectively. There is a higher incidence of hematoma in the mastectomy group than in the BCS group (44.4% vs. 23.9%, P=0.005). In BCS group, the positive margin was found in 7 patients at first examination including four focals with re-excision, two extensive with mastectomy and one focal but refusing further surgery. The ultimate success rate of BCS was 95.5%. Margin positivity correlated with tumor residual (P=0.044) but not with hematoma. Conclusions: Mammotome biopsy might lead to hematoma and tumor residual; however, it is not the determinant factor for a surgery option, and BCS is feasible through a complete excision of tumor residual to acquire negative margin.
- Open Access
- 16 July 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (8) , 1-10
Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway
Melatonin has been reported to have tumor-suppressive effects via comprehensive molecular mechanisms, and long non-coding RNAs (lncRNAs) may participate in this process. However, the mechanism by which melatonin affects the function of lncRNAs in triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is still unknown. Therefore, we aimed to investigate the differentially expressed mRNAs and lncRNAs in melatonin-treated TNBC cells and the interaction mechanisms. Microarray analyses were performed to identify differentially expressed mRNAs and lncRNAs in TNBC cell lines after melatonin treatment. To explore the functions and underlying mechanisms of the mRNAs and lncRNAs candidates, a series of in vitro experiments were conducted, including CCK-8, Transwell, colony formation, luciferase reporter gene, and RNA immunoprecipitation (RIP) assays, and mouse xenograft models were established. We found that after melatonin treatment, FUNDC1 and lnc049808 downregulated in TNBC cell lines. Knockdown of FUNDC1 and lnc049808 inhibited TNBC cell proliferation, invasion, and metastasis. Moreover, lnc049808 and FUNDC1 acted as competing endogenous RNAs (ceRNAs) for binding to miR-101. These findings indicated that melatonin inhibited TNBC progression through the lnc049808-FUNDC1 pathway and melatonin could be used as a potential therapeutic agent for TNBC.
- 16 July 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (8) , 1-10
Open AccessMelatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway
Melatonin has been reported to have tumor-suppressive effects via comprehensive molecular mechanisms, and long non-coding RNAs (lncRNAs) may participate in this process. However, the mechanism by which melatonin affects the function of lncRNAs in triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is still unknown. Therefore, we aimed to investigate the differentially expressed mRNAs and lncRNAs in melatonin-treated TNBC cells and the interaction mechanisms. Microarray analyses were performed to identify differentially expressed mRNAs and lncRNAs in TNBC cell lines after melatonin treatment. To explore the functions and underlying mechanisms of the mRNAs and lncRNAs candidates, a series of in vitro experiments were conducted, including CCK-8, Transwell, colony formation, luciferase reporter gene, and RNA immunoprecipitation (RIP) assays, and mouse xenograft models were established. We found that after melatonin treatment, FUNDC1 and lnc049808 downregulated in TNBC cell lines. Knockdown of FUNDC1 and lnc049808 inhibited TNBC cell proliferation, invasion, and metastasis. Moreover, lnc049808 and FUNDC1 acted as competing endogenous RNAs (ceRNAs) for binding to miR-101. These findings indicated that melatonin inhibited TNBC progression through the lnc049808-FUNDC1 pathway and melatonin could be used as a potential therapeutic agent for TNBC.
- Open Access
- 1 January 2021
- Published by Elsevier in EBioMedicine
- Vol. 63, 103137
Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis
- 1 January 2021
- Published by Elsevier in EBioMedicine
- Vol. 63, 103137
Open AccessDiscordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis